首页> 外文期刊>Trials >The value of post-operative antibiotic therapy after laparoscopic appendectomy for complicated acute appendicitis: a prospective, randomized, double-blinded, placebo-controlled phase III study (ABAP study)
【24h】

The value of post-operative antibiotic therapy after laparoscopic appendectomy for complicated acute appendicitis: a prospective, randomized, double-blinded, placebo-controlled phase III study (ABAP study)

机译:腹腔镜后术后抗生素治疗的价值对复杂的急性阑尾炎(急性急性阑尾炎):一项前瞻性,随机,双盲,安慰剂控制第三期研究(ABAP研究)

获取原文
           

摘要

BACKGROUND:Approximately 30% of appendectomies are for complicated acute appendicitis (CAA). With laparoscopy, the main post-operative complication is deep abscesses (12% of cases of CAA, versus 4% for open surgery). A recent cohort study compared short and long courses of postoperative antibiotic therapy in patients with CAA. There was no significant intergroup difference in the post-operative complication rate (12% of organ/space surgical site infection (SSI)). Moreover, antibiotic therapy is increasingly less indicated for other situations (non-complicated appendicitis, post-operative course of cholecystitis, perianal abscess), calling into question whether post-operative antibiotic therapy is required after laparoscopic appendectomy for CAA.METHODS/DESIGN:This study is a prospective, multicenter, parallel-group, randomized (1:1), double-blinded, placebo-controlled, phase III non-inferiority study with blind evaluation of the primary efficacy criterion. The primary objective is to evaluate the impact of the absence of post-operative antibiotic therapy on the organ/space surgical site infection (SSI) rate in patients presenting with CAA (other than in cases of generalized peritonitis). Patients in the experimental group will receive at least one dose of preoperative and perioperative antibiotic therapy (2?g ceftriaxone by intravenous injection every 24?h up to the operation) and metronidazole (500?mg by intravenous injection every 8?h up to the operation) and, in the post-operative period, a placebo for ceftriaxone (2?g/24?h in one intravenous injection) and a placebo for metronidazole (1500?mg/24?h in three intravenous injections, for 3 days). In the control group, patients will receive at least one dose of preoperative and perioperative antibiotic therapy (2?g ceftriaxone by intravenous injection every 24?h up to the operation) and metronidazole (500?mg by intravenous injection every 8?h up to the operation) and, in the post-operative period, antibiotic therapy (ceftriaxone 2?g/24?h and metronidazole 1500?mg/24?h for 3 days). In the event of allergy to ceftriaxone, it will be replaced by levofloxacin (500?mg/24?h in one intravenous injection, for 3 days). The expected organ space SSI rate is 12% in the population of patients with CAA operated on by laparoscopy. With a non-inferiority margin of 5%, a two-sided alpha risk of 5%, a beta risk of 20%, and a loss-to-follow-up rate of 10%, the calculated sample size is 1476 included patients, i.e., 738 per group. Due to three interim analyses at 10%, 25%, and 50% of the planned sample size, the total sample size increases to 1494 patients (747 per arm).TRIAL REGISTRATION:Ethical authorization by the Comité de Protection des Personnes and the Agence Nationale de Sécurité du Médicament: ID-RCB 2017-00334-59. Registered on ClinicalTrials.gov (NCT03688295) on 28 September 2018.
机译:背景:大约30%的阑尾切除术用于复杂的急性阑尾炎(CAA)。用腹腔镜检查,主要的术后并发症是深度脓肿(12%的CAA病例,开放手术的4%)。最近的队列研究比较了CAA患者术后抗生素治疗的短期和长期疗程。术后并发症率没有显着的杂交差异(12%的器官/太空手术部位感染(SSI))。此外,对于其他情况(非复杂的阑尾炎,胆囊炎的术后疗程,胆囊炎,肛周脓肿)表明,抗生素治疗越来越少表明,呼吁腹腔镜阑尾切除术后是否需要术后抗生素治疗。方法/设计:这研究是一种前瞻性,多中心,并行组,随机(1:1),双盲,安慰剂对照,相III非劣级研究,具有初级疗效标准的盲评估。主要目的是评估缺乏术后抗生素治疗的影响对患有CAA的患者的器官/空间手术部位感染(SSI)率(除了广义腹膜炎的情况之外)。实验组中的患者将至少术前和围手术期抗生素治疗(每24?H静脉注射术前术前和围手术期抗生素治疗(每24次静脉注射)和甲硝唑(每8静脉注射500毫克)操作)和,在术后期间,一个用于头孢曲松的安慰剂(一个静脉注射喷射中的2?G /24μm)和甲硝唑的安慰剂(在三个静脉注射中,3天在三个静脉内注射中的1500毫克/24μl。 。在对照组中,患者将至少通过静脉内注射一次术前和围手术期抗生素治疗(每24?H静脉注射到操作)和甲硝唑(每8静脉注射500毫克)该操作)和,在术后时期,抗生素治疗(头孢曲松2?G / 24?H和甲硝唑1500?Mg / 24?H持续3天)。在对头孢菌隆的发生过敏的情况下,它将被左氧氟沙星(在一个静脉内注射中的500×mg /24μl)取代3天)。通过腹腔镜检查的CAA患者人口中预期的器官空间SSI率为12%。具有5%的非较低余量,双面α风险为5%,β风险为20%,损失率为10%,计算的样品大小为1476名患者,即每组738。由于三个临时分析以10%,25%和50%的计划样本尺寸,总样本大小增加到1494名患者(每只手臂747).trial注册:Comitéde保护的道德授权des personnes和agence Talitale deSécuritéduMédicament:ID-RCB 2017-00334-59。 2018年9月28日在ClinicalTrials.gov(NCT03688295)上注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号